Bi CNU en es it fr

Bi CNU Brand names, Bi CNU Analogs

Bi CNU Brand Names Mixture

  • No information avaliable

Bi CNU Chemical_Formula


Bi CNU RX_link

Bi CNU fda sheet

Bi CNU msds (material safety sheet)


Bi CNU Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Bi CNU Molecular Weight

214.049 g/mol

Bi CNU Melting Point

31 oC

Bi CNU H2O Solubility

< 0.1 g/100 mL at 18 °C

Bi CNU State




Bi CNU Dosage Forms

Powder for solution; Wafer

Bi CNU Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Bi CNU Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Bi CNU Absorption

5 to 28% bioavailability

Bi CNU side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Bi CNU Patient Information

No information avaliable

Bi CNU Organisms Affected

Humans and other mammals